Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells

Miyake,Keitaro; Takano,Naoharu; Kazama,Hiromi; Kikuchi,Hiroyuki; Hiramoto,Masaki; Tsukahara,Kiyoaki; Miyazawa,Keisuke

doi:10.3892/ijo.2022.5344

Ricolinostat enhances adavosertib‑induced mitotic catastrophe in TP53‑mutated head and neck squamous cell carcinoma cells

Authors:
- Keitaro Miyake
- Naoharu Takano
- Hiromi Kazama
- Hiroyuki Kikuchi
- Masaki Hiramoto
- Kiyoaki Tsukahara
- Keisuke Miyazawa
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University Hospital, Shinjuku‑ku, Tokyo 160‑0023, Japan, Department of Biochemistry, Tokyo Medical University, Shinjuku‑ku, Tokyo 160‑8402, Japan, Department of Preventive Medicine and Public Health, Tokyo Medical University, Shinjuku‑ku, Tokyo 160‑8402, Japan
Published online on: March 28, 2022 https://doi.org/10.3892/ijo.2022.5344
Article Number: 54
Copyright: © Miyake et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

TP53 mutation is one of the most frequent gene mutations in head and neck squamous cell carcinoma (HNSCC) and could be a potential therapeutic target. Recently, the WEE1 G2 checkpoint kinase (WEE1) inhibitor adavosertib (Adv) has attracted attention because of its selective cytotoxicity against TP53‑mutated cells and has shown promising activity in early phase clinical trials. In the present study, it was demonstrated that combined treatment with Adv and a selective histone deacetylase 6 (HDAC6) inhibitor, ricolinostat (RCS), synergistically enhanced cell death induction in four out of five HNSCC cell lines with TP53 mutation (CAL27, SAS, HSC‑3, and OSC‑19), one HNSCC cell line with impaired TP53 function by HPV‑infection (UPCI‑SCC154), and TP53‑knockout human lung cancer cell line (A549 TP53‑KO), but not in TP53 wild‑type A549 cells. Time‑lapse imaging showed that RCS enhanced the Adv‑induced mitotic catastrophe. Consistent with this, RCS treatment suppressed checkpoint kinase 1 (Chk1) (Ser345) phosphorylation and co‑administration of RCS with Adv suppressed cyclin‑dependent kinase 1 (Tyr15) phosphorylation along with increased expression of γ‑H2A.X, a marker of DNA double‑strand breaks in CAL27 cells. These data showed that RCS enhanced Adv‑induced premature mitotic entry and cell death induction in the mitotic phase. However, although HDAC6 knockdown enhanced Adv‑induced cell death with γ‑H2A.X elevation, HDAC6 knockdown did not repress Chk1 phosphorylation in CAL27 cells. Our data demonstrated that the co‑administration of RCS with Adv in HNSCC cells resulted in the suppression of Chk1 activity, leading to synergistically enhanced apoptosis via mitotic catastrophe in a p53‑dependent manner. This enhanced cell death appeared to be partially mediated by the inhibition of HDAC6 activity by RCS.

View Figures

View References

1	Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
2	Agrawal N, Frederick MJ, Pickering CR, Bettegowda C, Chang K, Li RJ, Fakhry C, Xie TX, Zhang J, Wang J, et al: Exome sequencing of head and neck squamous cell carcinoma reveals inactivating mutations in NOTCH1. Science. 333:1154–1157. 2011. View Article : Google Scholar : PubMed/NCBI
3	Stransky N, Egloff AM, Tward AD, Kostic AD, Cibulskis K, Sivachenko A, Kryukov GV, Lawrence MS, Sougnez C, McKenna A, et al: The mutational landscape of head and neck squamous cell carcinoma. Science. 333:1157–1160. 2011. View Article : Google Scholar : PubMed/NCBI
4	Wang X and Sun Q: TP53 mutations, expression and interaction networks in human cancers. Oncotarget. 8:624–643. 2017. View Article : Google Scholar :
5	Scheffner M, Werness BA, Huibregtse JM, Levine AJ and Howley PM: The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell. 63:1129–1136. 1990. View Article : Google Scholar : PubMed/NCBI
6	Indovina P and Giordano A: Targeting the checkpoint kinase WEE1: Selective sensitization of cancer cells to DNA-damaging drugs. Cancer Biol Ther. 9:523–525. 2010. View Article : Google Scholar : PubMed/NCBI
7	Hirai H, Arai T, Okada M, Nishibata T, Kobayashi M, Sakai N, Imagaki K, Ohtani J, Sakai T, Yoshizumi T, et al: MK-1775, a small molecule Wee1 inhibitor, enhances anti-tumor efficacy of various DNA-damaging agents, including 5-fluorouracil. Cancer Biol Ther. 9:514–522. 2010. View Article : Google Scholar : PubMed/NCBI
8	Den Haese GJ, Walworth N, Carr AM and Gould KL: The Wee1 protein kinase regulates T14 phosphorylation of fission yeast Cdc2. Mol Biol Cell. 6:371–385. 1995. View Article : Google Scholar : PubMed/NCBI
9	Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI
10	Castedo M, Perfettini JL, Roumier T, Andreau K, Medema R and Kroemer G: Cell death by mitotic catastrophe: A molecular definition. Oncogene. 23:2825–2837. 2004. View Article : Google Scholar : PubMed/NCBI
11	Vitale I, Galluzzi L, Castedo M and Kroemer G: Mitotic catastrophe: A mechanism for avoiding genomic instability. Nat Rev Mol Cell Biol. 12:385–392. 2011. View Article : Google Scholar : PubMed/NCBI
12	Meng X, Bi J, Li Y, Yang S, Zhang Y, Li M, Liu H, Li Y, McDonald ME, Thiel KW, et al: AZD1775 increases sensitivity to olaparib and gemcitabine in cancer cells with p53 mutations. Cancers (Basel). 10:1492018. View Article : Google Scholar
13	Lin X, Chen D, Zhang C, Zhang X, Li Z, Dong B, Gao J and Shen L: Augmented antitumor activity by olaparib plus AZD1775 in gastric cancer through disrupting DNA damage repair pathways and DNA damage checkpoint. J Exp Clin Cancer Res. 37:1292018. View Article : Google Scholar : PubMed/NCBI
14	Prystowsky MB, Adomako A, Smith RV, Kawachi N, McKimpson W, Atadja P, Chen Q, Schlecht NF, Parish JL, Childs G, et al: The histone deacetylase inhibitor LBH589 inhibits expression of mitotic genes causing G2/M arrest and cell death in head and neck squamous cell carcinoma cell lines. J Pathol. 218:467–477. 2009. View Article : Google Scholar : PubMed/NCBI
15	Iglesias-Linares A, Yañez-Vico RM and González-Moles MA: Potential role of HDAC inhibitors in cancer therapy: Insights into oral squamous cell carcinoma. Oral Oncol. 46:323–329. 2010. View Article : Google Scholar : PubMed/NCBI
16	Lu YS, Kashida Y, Kulp SK, Wang YC, Wang D, Hung JH, Tang M, Lin ZZ, Chen TJ, Cheng AL, et al: Efficacy of a novel histone deacetylase inhibitor in murine models of hepatocellular carcinoma. Hepatology. 46:1119–1130. 2007. View Article : Google Scholar : PubMed/NCBI
17	Ozaki K, Kishikawa F, Tanaka M, Sakamoto T, Tanimura S and Kohno M: Histone deacetylase inhibitors enhance the chemosensitivity of tumor cells with cross-resistance to a wide range of DNA-damaging drugs. Cancer Sci. 99:376–384. 2008. View Article : Google Scholar : PubMed/NCBI
18	Ji M, Li Z, Lin Z and Chen L: Antitumor activity of the novel HDAC inhibitor CUDC-101 combined with gemcitabine in pancreatic cancer. Am J Cancer Res. 8:2402–2418. 2018.
19	Zhou L, Zhang Y, Chen S, Kmieciak M, Leng Y, Lin H, Rizzo KA, Dumur CI, Ferreira-Gonzalez A, Dai Y and Grant S: A regimen combining the Wee1 inhibitor AZD1775 with HDAC inhibitors targets human acute myeloid leukemia cells harboring various genetic mutations. Leukemia. 29:807–818. 2015. View Article : Google Scholar :
20	Qi W, Zhang W, Edwards H, Chu R, Madlambayan GJ, Taub JW, Wang Z, Wang Y, Li C, Lin H and Ge Y: Synergistic anti-leukemic interactions between panobinostat and MK-1775 in acute myeloid leukemia ex vivo. Cancer Biol Ther. 16:1784–1793. 2015. View Article : Google Scholar : PubMed/NCBI
21	Tanaka N, Patel AA, Tang L, Silver NL, Lindemann A, Takahashi H, Jaksik R, Rao X, Kalu NN, Chen TC, et al: Replication stress leading to apoptosis within the S-phase contributes to synergism between vorinostat and AZD1775 in HNSCC harboring high-risk TP53 mutation. Clin Cancer Res. 23:6541–6554. 2017. View Article : Google Scholar : PubMed/NCBI
22	Hattori K, Takano N, Kazama H, Moriya S, Miyake K, Hiramoto M, Tsukahara K and Miyazawa K: Synergistic non-apoptotic cell death induction by simultaneously targeting proteasome with bortezomib and HDAC6 with ricolinostat in head and neck tumor cells. Oncol Lett. 22:6802021. View Article : Google Scholar
23	Wickström SA, Masoumi KC, Khochbin S, Fässler R and Massoumi R: CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin. Embo J. 29:131–144. 2010. View Article : Google Scholar
24	Kim IA, No M, Lee JM, Shin JH, Oh JS, Choi EJ, Kim IH, Atadja P and Bernhard EJ: Epigenetic modulation of radiation response in human cancer cells with activated EGFR or HER-2 signaling: Potential role of histone deacetylase 6. Radiother Oncol. 92:125–132. 2009. View Article : Google Scholar : PubMed/NCBI
25	Namdar M, Perez G, Ngo L and Marks PA: Selective inhibition of histone deacetylase 6 (HDAC6) induces DNA damage and sensitizes transformed cells to anticancer agents. Proc Natl Acad Sci USA. 107:20003–20008. 2010. View Article : Google Scholar : PubMed/NCBI
26	Wang L, Xiang S, Williams KA, Dong H, Bai W, Nicosia SV, Khochbin S, Bepler G and Zhang X: Depletion of HDAC6 enhances cisplatin-induced DNA damage and apoptosis in non-small cell lung cancer cells. PLoS One. 7:e442652012. View Article : Google Scholar : PubMed/NCBI
27	Toriyama K, Takano N, Kokuba H, Kazama H, Moriya S, Hiramoto M, Abe S and Miyazawa K: Azithromycin enhances the cytotoxicity of DNA-damaging drugs via lysosomal membrane permeabilization in lung cancer cells. Cancer Sci. 112:3324–3337. 2021. View Article : Google Scholar : PubMed/NCBI
28	Pemble H, Kumar P, van Haren J and Wittmann T: GSK3-mediated CLASP2 phosphorylation modulates kinetochore dynamics. J Cell Sci. 130:1404–1412. 2017.PubMed/NCBI
29	Spangle JM, Ghosh-Choudhury N and Munger K: Activation of cap-dependent translation by mucosal human papillomavirus E6 proteins is dependent on the integrity of the LXXLL binding motif. J Virol. 86:7466–7472. 2012. View Article : Google Scholar : PubMed/NCBI
30	Szalai P and Engedal N: An image-based assay for high-throughput analysis of cell proliferation and cell death of adherent cells. Bio-protocol. 8:e28352018. View Article : Google Scholar : PubMed/NCBI
31	Vakifahmetoglu H, Olsson M and Zhivotovsky B: Death through a tragedy: Mitotic catastrophe. Cell Death Differ. 15:1153–1162. 2008. View Article : Google Scholar : PubMed/NCBI
32	Ghelli Luserna di Rorà A, Cerchione C, Martinelli G and Simonetti G: A WEE1 family business: Regulation of mitosis, cancer progression, and therapeutic target. J Hematol Oncol. 13:1262020. View Article : Google Scholar : PubMed/NCBI
33	Santo L, Hideshima T, Kung AL, Tseng JC, Tamang D, Yang M, Jarpe M, van Duzer JH, Mazitschek R, Ogier WC, et al: Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. Blood. 119:2579–2589. 2012. View Article : Google Scholar : PubMed/NCBI
34	Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JP, Bui TN, Vijayaraghavan S, Evans KW, et al: Cyclin E overexpression sensitizes triple-negative breast cancer to Wee1 kinase inhibition. Clin Cancer Res. 24:6594–6610. 2018. View Article : Google Scholar : PubMed/NCBI
35	Young LA, O'Connor LO, de Renty C, Veldman-Jones MH, Dorval T, Wilson Z, Jones DR, Lawson D, Odedra R, Maya-Mendoza A, et al: Differential activity of ATR and WEE1 inhibitors in a highly sensitive subpopulation of DLBCL linked to replication stress. Cancer Res. 79:3762–3775. 2019. View Article : Google Scholar : PubMed/NCBI
36	Do K, Doroshow JH and Kummar S: Wee1 kinase as a target for cancer therapy. Cell Cycle. 12:3159–3164. 2013. View Article : Google Scholar : PubMed/NCBI
37	Cuneo KC, Morgan MA, Sahai V, Schipper MJ, Parsels LA, Parsels JD, Devasia T, Al-Hawaray M, Cho CS, Nathan H, et al: Dose escalation trial of the Wee1 inhibitor Adavosertib (AZD1775) in combination with gemcitabine and radiation for patients with locally advanced pancreatic cancer. J Clin Oncol. 37:2643–2650. 2019. View Article : Google Scholar : PubMed/NCBI
38	Leijen S, van Geel RM, Sonke GS, de Jong D, Rosenberg EH, Marchetti S, Pluim D, van Werkhoven E, Rose S, Lee MA, et al: Phase II study of WEE1 inhibitor AZD1775 plus carboplatin in patients with TP53-mutated ovarian cancer refractory or resistant to first-line therapy within 3 months. J Clin Oncol. 34:4354–4361. 2016. View Article : Google Scholar : PubMed/NCBI
39	Lheureux S, Cabanero M, Cristea MC, Mantia-Smaldone G, Olawaiye A, Ellard S, Weberpals JI, Hendrickson AEW, Fleming GF, Welch S, et al: A randomized double-blind placebo-controlled phase II trial comparing gemcitabine monotherapy to gemcitabine in combination with adavosertib in women with recurrent, platinum resistant epithelial ovarian cancer: A trial of the Princess Margaret, California, Chicago and Mayo Phase II Consortia. J Clin Oncol. 37:5518. 2019. View Article : Google Scholar
40	Oza AM, Estevez-Diz M, Grischke EM, Hall M, Marmé F, Provencher D, Uyar D, Weberpals JI, Wenham RM, Laing N, et al: A Biomarker-enriched, randomized phase II trial of adavosertib (AZD1775) plus paclitaxel and carboplatin for women with platinum-sensitive TP53-mutant ovarian cancer. Clin Cancer Res. 26:4767–4776. 2020. View Article : Google Scholar : PubMed/NCBI
41	Liu JF, Xiong N, Campos SM, Wright AA, Krasner C, Schumer S, Horowitz N, Veneris J, Tayob N, Morrissey S, et al: Phase II study of the WEE1 inhibitor adavosertib in recurrent uterine serous carcinoma. J Clin Oncol. 39:1531–1539. 2021. View Article : Google Scholar : PubMed/NCBI
42	Ku BM, Bae YH, Koh J, Sun JM, Lee SH, Ahn JS, Park K and Ahn MJ: Mutational status of TP53 defines the efficacy of Wee1 inhibitor AZD1775 in KRAS-mutant non-small cell lung cancer. Oncotarget. 8:67526–67537. 2017. View Article : Google Scholar : PubMed/NCBI
43	Kreahling JM, Foroutan P, Reed D, Martinez G, Razabdouski T, Bui MM, Raghavan M, Letson D, Gillies RJ and Altiok S: Wee1 inhibition by MK-1775 leads to tumor inhibition and enhances efficacy of gemcitabine in human sarcomas. PLoS One. 8:e575232013.Epub ahead of print. View Article : Google Scholar : PubMed/NCBI
44	Moses N, Zhang M, Wu JY, Hu C, Xiang S, Geng X, Chen Y, Bai W, Zhang YW, Bepler G and Zhang XM: HDAC6 regulates radiosensitivity of non-small cell lung cancer by promoting degradation of Chk1. Cells. 9:22372020. View Article : Google Scholar :
45	Hubbert C, Guardiola A, Shao R, Kawaguchi Y, Ito A, Nixon A, Yoshida M, Wang XF and Yao TP: HDAC6 is a microtubule-associated deacetylase. Nature. 417:455–458. 2002. View Article : Google Scholar : PubMed/NCBI
46	Kovacs JJ, Murphy PJ, Gaillard S, Zhao X, Wu JT, Nicchitta CV, Yoshida M, Toft DO, Pratt WB and Yao TP: HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol Cell. 18:601–607. 2005. View Article : Google Scholar : PubMed/NCBI
47	Zhang X, Yuan Z, Zhang Y, Yong S, Salas-Burgos A, Koomen J, Olashaw N, Parsons JT, Yang XJ, Dent SR, et al: HDAC6 modulates cell motility by altering the acetylation level of cortactin. Mol Cell. 27:197–213. 2007. View Article : Google Scholar : PubMed/NCBI
48	Lee YS, Lim KH, Guo X, Kawaguchi Y, Gao Y, Barrientos T, Ordentlich P, Wang XF, Counter CM and Yao TP: The cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis. Cancer Res. 68:7561–7569. 2008. View Article : Google Scholar : PubMed/NCBI
49	Lernoux M, Schnekenburger M, Dicato M and Diederich M: Anti-cancer effects of naturally derived compounds targeting histone deacetylase 6-related pathways. Pharmacol Res. 129:337–356. 2018. View Article : Google Scholar
50	Bradbury CA, Khanim FL, Hayden R, Bunce CM, White DA, Drayson MT, Craddock C and Turner BM: Histone deacetylases in acute myeloid leukaemia show a distinctive pattern of expression that changes selectively in response to deacetylase inhibitors. Leukemia. 19:1751–1759. 2005. View Article : Google Scholar : PubMed/NCBI
51	Sakuma T, Uzawa K, Onda T, Shiiba M, Yokoe H, Shibahara T and Tanzawa H: Aberrant expression of histone deacetylase 6 in oral squamous cell carcinoma. Int J Oncol. 29:117–124. 2006.PubMed/NCBI
52	Bazzaro M, Lin Z, Santillan A, Lee MK, Wang MC, Chan KC, Bristow RE, Mazitschek R, Bradner J and Roden RB: Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. Clin Cancer Res. 14:7340–7347. 2008. View Article : Google Scholar : PubMed/NCBI
53	Cao J, Lv W, Wang L, Xu J, Yuan P, Huang S, He Z and Hu J: Ricolinostat (ACY-1215) suppresses proliferation and promotes apoptosis in esophageal squamous cell carcinoma via miR-30d/PI3K/AKT/mTOR and ERK pathways. Cell Death Dis. 9:8172018. View Article : Google Scholar : PubMed/NCBI
54	Kanno K, Kanno S, Nitta H, Uesugi N, Sugai T, Masuda T, Wakabayashi G and Maesawa C: Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells. Oncol Rep. 28:867–873. 2012. View Article : Google Scholar : PubMed/NCBI
55	Chuang MJ, Wu ST, Tang SH, Lai XM, Lai HC, Hsu KH, Sun KH, Sun GH, Chang SY, Yu DS, et al: The HDAC inhibitor LBH589 induces ERK-dependent prometaphase arrest in prostate cancer via HDAC6 inactivation and down-regulation. PLoS One. 8:e734012013. View Article : Google Scholar : PubMed/NCBI
56	Vicente JJ and Wordeman L: The quantification and regulation of microtubule dynamics in the mitotic spindle. Curr Opin Cell Biol. 60:36–43. 2019. View Article : Google Scholar : PubMed/NCBI
57	Ling L, Hu F, Ying X, Ge J and Wang Q: HDAC6 inhibition disrupts maturational progression and meiotic apparatus assembly in mouse oocytes. Cell Cycle. 17:550–556. 2018. View Article : Google Scholar :